Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’s NHL market owing to a favorable and well-established clinical profile, particularly as part of the R-CHOP chemotherapy regimen. However, rituximab’s market dominance is likely to be challenged by novel, emerging targeted therapies that we expect will launch in a few years. The launch of these therapies will allow the Chinese non-Hodgkin’s lymphoma (NHL) market to grow significantly during the forecast period, despite the launch of cost-effective biosimilars and generics of rituximab and lenalidomide, respectively, starting in 2019. The high unmet need for effective targeted therapies for NHL in China presents a commercial opportunity for developers. Additionally, the ongoing reforms in the regulatory and access and reimbursement landscape of China will encourage multinational corporations (MNCs) to enter the market.
- How large is China’s drug-treatable non-Hodgkin’s lymphoma population, and how will the drug-treatment rate change during the forecast period?
- What are the most commercially relevant drugs in China’s non-Hodgkin’s lymphoma market, and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the major market access considerations for key therapies in the non-Hodgkin’s lymphoma pipeline in China? What sales/uptake could they secure in non-Hodgkin’s lymphoma?
- What are the key drivers and constraints in the Chinese non-Hodgkin’s lymphoma market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other DRG research.
Diagnosed incidence of non-Hodgkin’s lymphoma in urban versus rural China; clinically relevant and market-relevant drug-treatable populations
10-year, annualized, drug-level sales and patient shares of key non-Hodgkin’s lymphoma regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 5+ drugs; Phase II: 10+ drugs; coverage of select preclinical and Phase I products
- Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Geographic Focus: China - China In-Depth | China
- China-In-Depth-Non-Hodgkin's Lymphoma
Author(s): Karan Verma, MSc; Stephanie Niquita
Karan is a Senior Analyst with the China-in-Depth team at Decision Resources Group, where he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market.
Before joining DRG, Karan was associated with Aranca, a boutique management consulting firm. Prior to that, he was working with Frost & Sullivan, a global healthcare consulting firm, where he was helping clients devise market entry strategies, conducting technology feasibility studies, and doing competitive intelligence for new product development. His prior experience also includes a short KTP program with the University of Southampton, UK. Karan has earned his MSc in Biomedical Engineering from the University of Warwick, and B.E. in Biomedical Engineering from Maharshi Dayanand University, Haryana, India.
Stephanie Niquita works as an associate epidemiologist at Decision Resources Group. Stephanie holds a masters in public health specializing in epidemiology from TISS, Mumbai and a medical degree from Hubei University of Chinese Medicine, People’s Republic of China. She has been trained as a community physician and has also supervised and coordinated various governmental and non-governmental public health projects.